financetom
Business
financetom
/
Business
/
Sagicor Financial Q3 profit rises on higher equity market returns
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Sagicor Financial Q3 profit rises on higher equity market returns
Nov 13, 2025 5:02 AM

Overview

* Sagicor Q3 core earnings to shareholders rise 45% yr/yr, driven by strong business momentum

* Net income to shareholders for Q3 increases 37% yr/yr, reflecting higher equity market returns

* Company maintains strong capital position with stable Group LICAT ratio of 141%

Outlook

* Sagicor expects impact from Hurricane Melissa on Caribbean operations

* Company maintains Group LICAT ratio at 141%

* Sagicor declares Q4 dividend of US 6.75¢ per share

Result Drivers

* INSURANCE EXPERIENCE - Sagicor Canada saw gains from favorable mortality experience, boosting core earnings

* MARKET IMPACT - Higher equity market returns and interest rate movements contributed to net income increase

* REPRICING INITIATIVES - Caribbean segments benefited from repricing initiatives, supporting earnings growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Core $35 mln

Earnings

Q3 Net $81 mln

Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* Wall Street's median 12-month price target for Sagicor Financial Company Ltd ( SGCFF ) is C$11.00, about 25.5% above its November 12 closing price of C$8.20

* The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 7 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
IT staffing firm ASGN Q3 adjusted EPS beats estimates on growth in consulting business
IT staffing firm ASGN Q3 adjusted EPS beats estimates on growth in consulting business
Oct 22, 2025
Overview * ASGN ( ASGN ) Q3 revenue was $1.01 bln, sligthly beating analyst expectations * Adjusted EPS for Q3 was $1.31, surpassing consensus estimates * Company repurchased 0.9 mln shares for $46 mln, reflecting confidence in financial position Outlook * Company expects Q4 2025 revenue between $960 mln and $980 mln * ASGN ( ASGN ) projects Q4 adjusted...
Kinder Morgan Q3 Adjusted Earnings, Revenue Increase
Kinder Morgan Q3 Adjusted Earnings, Revenue Increase
Oct 22, 2025
04:29 PM EDT, 10/22/2025 (MT Newswires) -- Kinder Morgan ( KMI ) reported Q3 adjusted earnings late Wednesday of $0.29 per share, up from $0.25 a year earlier. Analysts polled by FactSet expected $0.29. Revenue for the quarter ended Sept. 30 was $4.15 billion, up from $3.70 billion a year earlier. Analysts surveyed by FactSet expected $3.98 billion. Kinder Morgan...
Eagle Bancorp's Q3 net loss of $67.5 mln misses analyst expectations
Eagle Bancorp's Q3 net loss of $67.5 mln misses analyst expectations
Oct 22, 2025
Overview * Eagle Bancorp ( EGBN ) Q3 net loss of $67.5 mln, missing analyst expectations * Net interest income rose slightly to $68.2 mln, driven by lower funding costs * Noninterest income fell due to $3.6 mln loan sale loss and $2 mln security sale loss Outlook * Company did not provide specific guidance for future quarters or full...
Viking Therapeutics misses Q3 profit estimates
Viking Therapeutics misses Q3 profit estimates
Oct 22, 2025
Overview * Viking Therapeutics ( VKTX ) reports Q3 net loss of $90.8 mln, missing analyst expectations * Company maintains strong cash position of $715 mln to support ongoing clinical trials * VK2735 Phase 2 VENTURE study shows up to 12.2% weight loss, meeting primary endpoints Outlook * Company expects to complete VANQUISH-1 enrollment by end of 2025 * Viking...
Copyright 2023-2026 - www.financetom.com All Rights Reserved